Biomarkers Consortium – CSC Scientific Symposium

Each year, the Cancer Steering Committee (CSC), led by the FNIH and its co-chairs Drs. Gary Kelloff (NCI) and Eric Rubin (Merck), brings together experts from academia, pharmaceutical companies, biotechnology companies, not-for-profit organizations, the NIH and the FDA to participate in a scientific symposium to review advances in the field of biomarker and regulatory science that are relevant to the development of new public-private partnerships for precompetitive biomarkers. The FNIH Biomarkers Consortium’s (BC) CSC Symposium thus serves as a juncture each year to assess and recalibrate future directions in biomarker discovery and development.

The 2018 CSC Symposium will be held on November 5 and 6 in Bethesda, MD.


  • Discuss cutting edge science, including projects supported by the FNIH BC.
  • Inform the field of the latest developments in critical areas of biomarker science.
  • Guide CSC decision making and project planning.

Results & Accomplishments

Demonstrating the diversity of the biomarker science discussed, the 2016 and 2017 agendas showcased projects across the ecosystem of precision medicine and biomarker development, including MRD, liquid biopsy, novel imaging improvement, cell-free RNA and DNA research, and immuno-oncology. Cross-disease analysis of non-cancer biomarker initiatives also provided discussion to assess approaches for collaboration across the field of medicine.


2017 Symposium Agenda

2017 Symposium Overview

2016 Symposium Agenda

2016 Symposium Executive Summary

2015 Symposium Executive Summary


The FNIH invites private-sector support and involvement in the CSC Symposium. Learn more in this overview. If you are interested in sponsoring this event or need more information, please contact


Food and Drug Administration (FDA)
National Cancer Institute (NCI)


Stacey J. Adam, Ph.D., Director, Cancer,

Dana E. Connors, Scientific Project Manager, Cancer,